BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,067 filers reported holding BAXTER INTL INC in Q2 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $59,794,000 | +24.6% | 809,773 | +9.8% | 0.80% | +13.6% |
| Q1 2018 | $47,985,000 | -19.7% | 737,784 | -20.2% | 0.70% | -18.3% |
| Q4 2017 | $59,772,000 | +3.5% | 924,697 | +0.4% | 0.86% | -1.2% |
| Q3 2017 | $57,778,000 | +15.7% | 920,762 | +11.7% | 0.87% | +6.6% |
| Q2 2017 | $49,920,000 | +9.1% | 824,571 | -6.5% | 0.81% | +9.9% |
| Q1 2017 | $45,744,000 | +5294.3% | 882,074 | +4510.9% | 0.74% | +5185.7% |
| Q4 2016 | $848,000 | -6.9% | 19,130 | 0.0% | 0.01% | -6.7% |
| Q3 2016 | $911,000 | -7.2% | 19,130 | -11.9% | 0.02% | -25.0% |
| Q2 2016 | $982,000 | +169.8% | 21,720 | +149.1% | 0.02% | +150.0% |
| Q1 2016 | $364,000 | +9.3% | 8,720 | 0.0% | 0.01% | 0.0% |
| Q4 2015 | $333,000 | +38.8% | 8,720 | +19.3% | 0.01% | +33.3% |
| Q3 2015 | $240,000 | -22.1% | 7,310 | +66.1% | 0.01% | -14.3% |
| Q2 2015 | $308,000 | – | 4,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |